Pipeline

MP1000

Our target: inflammatory macrophages

MP1000 constitutes a class of small molecular anti-inflammatory drugs that act via a novel mechanism of action. The primary target of drugs from our MP1000 class are activated (inflammatory) macrophages. Macrophages are central regulators of the immune and inflammatory response.
These cells have often been described as the “conductors” of the immune response. They regulate and orchestrate the reaction of other immune cells to an assault by pathogens (bacteria, viruses), tissue damage or auto-immune reactions.

MP2000

Our target: cardiac muscle metabolism

MP2000 denotes a range of closely related drug compounds which are specific inhibitors of an enzyme called CPT1. These drugs inhibit the use of fatty-acids as primary energy source of the heart muscle and shift the heart metabolism towards the use of glucose as an alternative energy source. “Burning” of glucose needs less oxygen for the same amount of muscle energy.
Thus in patients with coronary disease and a reduced oxygen supply of the heart, the use of CPT1-inhibitors gives more pumping power to the heart without the need for more oxygen.

This is especially valuable in patients with severe heart failure (NYHA grade IV). 50% of these patients die within one year and there is a high medical need for additional pharmacologic treatment options. Leading cardiologists have noted that the therapeutic principle of drugs like MP2000 will lead to a new era of pharmacological treatment of heart disease.
The MP2000 class of molecules are the most specific and potent drugs known for this new treatment approach to chronic heart failure.